This inventor holds 2 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Cantab Biopharmaceuticals Patents Limited, Sequessome Technology Holdings Limited. Active years: 2017-2022.
Company Filing History:
1 out of 2 
1 out of 4 Years Active: 2017-2022
Title: John Charles Mayo: Innovator in Therapeutic Agents
Introduction
John Charles Mayo is a notable inventor based in London, GB. He has made significant contributions to the field of therapeutic agents, holding a total of 2 patents. His work focuses on improving the administration and effectiveness of therapeutic agents through innovative formulations.
Latest Patents
Mayo's latest patents include "Optimised Subcutaneous Therapeutic Agents" and "Vesicular Formulations." The first patent provides methods and dosage formulations for subcutaneous administration, where therapeutic agents are modified to enhance their hydrophilicity and molecular dimensions compared to their native state. This modification results in a lower C:C ratio than when the agent is delivered intravenously. The second patent relates to vesicular formulations specifically designed for the treatment of rosacea, including a method of administering these formulations to effectively treat the condition.
Career Highlights
Throughout his career, John Charles Mayo has worked with several companies, including Sequessome Technology Holdings Limited and Cantab Biopharmaceuticals Patents Limited. His experience in these organizations has allowed him to develop and refine his innovative ideas in the field of therapeutic agents.
Collaborations
Mayo has collaborated with notable individuals such as William Henry and Richard Wolf-Garraway. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
John Charles Mayo is a distinguished inventor whose work in therapeutic agents has led to significant advancements in medical treatments. His innovative patents and collaborations highlight his commitment to improving healthcare solutions.